Share on LinkedInShare on LinkedIn

ARTICLE · 31 AUGUST 2012

Developments: Legislative Proposals Confirm SR&ED Changes

PwC Management Services LP
Explore more from PwC Management Services LP

In the 2012 federal budget, the Department of Finance (Finance) announced a number of measures that reduce the benefits available under the Scientific Research and Experimental Development (SR&ED) tax incentive program.

CanadaFood, Drugs, Healthcare, Life Sciences
Vik Sachdev
Vik Sachdev

In the 2012 federal budget, the Department of Finance (Finance) announced a number of measures that reduce the benefits available under the Scientific Research and Experimental Development (SR&ED) tax incentive program.

Despite extensive industry feedback to reconsider or delay the measures, Finance has moved to implement their original, unmodified plans. Draft legislative proposals, released on August 14, 2012, include the following changes:

Eliminated

  • Capital expenditures for SR&ED will no longer qualify for investment tax credits (ITCs), including shared-use equipment previously claimable for partial ITCs.

Reduced

  • The rate used for the proxy method of claiming overhead expenditures will be reduced from 65% to 55%.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Register for freeORLog in

Related Articles

Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics

Read more about

Related Comparative Guides

See more popular content from

Article

More Than Skin Deep: Ontario Considers A Makeover Of Cosmetic Injection Rules

A regulatory shift now under consideration in Ontario could reshape how the province’s medical aesthetic clinics operate. The proposal, which would change how nurses are authorized to administer medical aesthetic services, invites a broader look at how Ontario currently regulates cosmetic injections and how the proposed changes would align the province more closely with the regulatory frameworks already in place elsewhere in Canada. While these procedures are often marketed as routine “spa” services, they remain medical acts that involve prescription products and carry clinical risks.
CanadaFood, Drugs, Healthcare, Life Sciences
Fasken
Fasken
Article

Life Sciences-Health Canada Takes Action Against Unauthorized Peptide Sales

On July 29, 2026, Health Canada announced that it had obtained a permanent injunction against a Québec-based company in connection with the sale of unauthorized injectable peptides in Canada. The announcement reflects Health Canada’s continued focus on peptide products and serves as a reminder that injectable peptides intended for human use are regulated as prescription drugs and are subject to Canada's drug regulatory framework.
CanadaFood, Drugs, Healthcare, Life Sciences
Fasken
Fasken
Article

Health Canada Updates Policies On Foreign Regulatory Actions, Summary Reporting, Compliance & Enforcement And Requests For New Data

Health Canada issued revised guidance on notifying Health Canada of foreign actions, effective October 1, 2026. The revised guidance clarifies the requirements to notify Health Canada of certain foreign regulatory actions specified in subsection C.01.050(2) of the Food and Drug Regulations in the specified foreign jurisdictions, which involve a serious risk of injury to human health and are relevant to the safety of the drug.
CanadaFood, Drugs, Healthcare, Life Sciences
Smart & Biggar
Smart & Biggar
Article

Health Canada Launches Clinical Trial Search Portal And Registration And Results Disclosure Guidance

While not currently legally binding, the guidance sets clear expectations for clinical trial registration and results disclosure and signals Health Canada’s broader push for transparency in clinical research. Health Canada describes this policy-first approach as a way to allow sponsors to adapt before potential regulatory requirements are introduced. For sponsors conducting clinical trials in Canada, the announcement therefore represents more than the launch of a new public-facing tool, it provides an indication of the direction of Canada’s evolving clinical trial framework.
CanadaFood, Drugs, Healthcare, Life Sciences
Fasken
Fasken
Article

Pharmaceutical And Life Sciences Sector Task Force Submits Final Report To The Ministers Of Health And Industry

The Pharmaceutical and Life Sciences Sector Task Force has released its final report addressing Canada's challenges in medication access, regulatory processes, and life sciences competitiveness. The report examines structural issues including lengthy reimbursement pathways, underperforming clinical trial environments, and erosion of domestic investment, while proposing 39 recommendation areas to strengthen Canada's health sovereignty and industrial strategy.
CanadaFood, Drugs, Healthcare, Life Sciences
Smart & Biggar
Smart & Biggar